scandinavian journal of immunology

Travel medicine and infectious disease

[1] a case of fulminant varicella infection with purpura fulminans, hepatitis, and rhabdomyolysis

[2] late-relapsing hepatitis after yellow fever

[3] clinical and biochemical features of autoimmune hepatitis in 36 pediatric patients características clínicas e bioquímicas da hepatite autoimune em 36 pacientes pediátricos

[4] pleural effusion- an unusual cause

[5] reflexões éticas acerca dos estudos de soroprevelência de hepatites virais ethical issues about seroprevalence studies on viral hepatitis

[6] carpal tunnel syndrome in hiv-positive patients coinfected with hcv

[7] prospek tanaman obat sebagai antihepatitis

[8] acute hepatitis in a child heterozygous for the i259v mefv gene variant

[9] the spectrum of cutaneous infection in diabetic patients with hepatitis c virus infection: a single-center study from egypt

[10] pruebas de laboratorio en el síndrome de gilbert consecutivo a hepatitis laboratory tests in gilbert's syndrome subsequent to hepatitis

[11] a prospective study of hepatitis during antituberculous treatment in taiwanese patients and a review of the literature

[12] micrornas in the evaluation and potential treatment of liver diseases

[13] proposed electronic medical record with emphasis on hepatitis diagnosis

[14] esteato-hepatite relacionada ao vírus da hepatite c: perfil clínico-histológico steatohepatitis related to hepatitis c virus: clinical and histological profiles

[15] role of hepatic deposited immunoglobulin g in the pathogenesis of liver damage in systemic lupus erythematosus

[16] exploitation of lipid components by viral and host proteins for hepatitis c virus infection

[17] diagnóstico in vivo da asma brônquica

[18] Quercetin treatment ameliorates inflammation and fibrosis in mice with nonalcoholic steatohepatitis.

[19] Quercetin treatment ameliorates inflammation and fibrosis in mice with nonalcoholic steatohepatitis.

[20] Synthesis and biological evaluation of (1,2,4)triazole[4,3-a]pyridine derivatives as potential therapeutic agents for concanavalin A-induced hepatitis.

[21] Gold nanoparticles and hepatitis B virus

[22] Prognostic profile of patients with non-viral hepatocellular carcinoma: A comparative study with hepatitis C virus-related hepatocellular carcinoma using data mining analysis.

[23] Cost-effectiveness of direct anti-viral agents for hepatitis C virus infection and a combined intervention of syringe access and medication assisted therapy for opioid use disorders in an injection drug use population.

[24] How expensive may drugs be? The example of hepatitis C drugs

[25] The average effective dose of 4-amino-5-(furan-2-yl)-4H-1 ,2,4-triazole-3-thiol in experimental hepatitis

[26] Prediction and Staging of Hepatic Fibrosis in Children with Hepatitis C Virus: A Machine Learning Approach.

[27] Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C

[28] Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience [Corrigendum]

[29] Current progress in the prevention of mother-to-child transmission of hepatitis B and resulting clinical and programmatic implications

[30] Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B

[31] Reactivation of herpesvirus in patients with hepatitis C treated with direct-acting antiviral agents

[32] Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study

[33] Prevalence and predictors of occult hepatitis C virus infection among Egyptian patients who achieved sustained virologic response to sofosbuvir/daclatasvir therapy: a multi-center study

[34] Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus [Erratum]

[35] Declining prevalence of hepatitis C virus among university students in one of the main governorates in Egypt

[36] Baseline hepatitis C virus resistance-associated substitutions present at frequencies lower than 15% may be clinically significant

[37] Poor adherence is a contributor to viral breakthrough in patients with chronic hepatitis B

[38] Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents

[39] Entecavir add-on or switch-to pegylated interferon improves HBsAg clearance in HBe antigen negative chronic hepatitis B patients

[40] Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse

[41] Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience

[42] Higher baseline viral diversity correlates with lower HBsAg decline following PEGylated interferon-alpha therapy in patients with HBeAg-positive chronic hepatitis B

[43] Serum hepatitis B core antibody levels predict HBeAg seroconversion in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analogs

[44] Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection

[45] Efficacy and safety of sofosbuvir–ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection

[46] Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China

[47] Detection of hepatitis C virus (HCV) among health care providers in an Egyptian university hospital: different diagnostic modalities

[48] Genotyping of HBV and tracking of resistance mutations in treatment-naïve patients with chronic hepatitis B

[49] Conceptual framework for outcomes research studies of hepatitis C: an analytical review

[50] Influence of host resistance on viral adaptation: hepatitis C virus as a case study

[51] Approaches to hepatitis C treatment and cure using NS5A inhibitors

[52] Safety and efficacy of entecavir for the treatment of chronic hepatitis B

[53] Current treatment of choice for chronic hepatitis C infection

[54] New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents

[55] New approaches in the management of chronic hepatitis B: role of tenofovir

[56] Hepatitis C virus-associated hepatocellular carcinoma as a second primary malignancy: exposing an overlooked presentation of liver cancer

[57] Decreased hepatocellular carcinoma tumor burden with the achievement of hepatitis C virus sustained virologic response: unlocking the potential of T-cell-mediated immunosurveillance

[58] Liver resection versus radiofrequency ablation for hepatitis B virus-related small hepatocellular carcinoma

[59] Clinical significance of vascular endothelial growth factor in hepatitis C related hepatocellular carcinoma in Egyptian patients

[60] Emerging role of dual antiplatelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma

[61] Telaprevir-containing regimen for treatment of hepatitis C virus infection in patients with hepatocellular carcinoma awaiting liver transplantation: a case series

[62] Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C

[63] Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience [Corrigendum]

[64] Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C

[65] Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience [Corrigendum]

[66] In Silico Screening of Aptamers Configuration against Hepatitis B Surface Antigen

[67] Seroprevalence of Hepatitis B Virus and Associated Factors among Health Professionals in University of Gondar Hospital, Northwest Ethiopia

[68] A Rare Case of Herpes Simplex Virus-2 Hepatitis with Negative Serology

[69] Current progress in the prevention of mother-to-child transmission of hepatitis B and resulting clinical and programmatic implications

[70] Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B

[71] Reactivation of herpesvirus in patients with hepatitis C treated with direct-acting antiviral agents

[72] Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study

[73] Prevalence and predictors of occult hepatitis C virus infection among Egyptian patients who achieved sustained virologic response to sofosbuvir/daclatasvir therapy: a multi-center study

[74] Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus [Erratum]

[75] Declining prevalence of hepatitis C virus among university students in one of the main governorates in Egypt

[76] Baseline hepatitis C virus resistance-associated substitutions present at frequencies lower than 15% may be clinically significant

[77] Poor adherence is a contributor to viral breakthrough in patients with chronic hepatitis B

[78] Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents

[79] Entecavir add-on or switch-to pegylated interferon improves HBsAg clearance in HBe antigen negative chronic hepatitis B patients

[80] Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse

[81] Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience

[82] Higher baseline viral diversity correlates with lower HBsAg decline following PEGylated interferon-alpha therapy in patients with HBeAg-positive chronic hepatitis B

[83] Serum hepatitis B core antibody levels predict HBeAg seroconversion in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analogs

[84] Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection

[85] Efficacy and safety of sofosbuvir–ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection

[86] Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China

[87] Detection of hepatitis C virus (HCV) among health care providers in an Egyptian university hospital: different diagnostic modalities

[88] Genotyping of HBV and tracking of resistance mutations in treatment-naïve patients with chronic hepatitis B

[89] Conceptual framework for outcomes research studies of hepatitis C: an analytical review

[90] Influence of host resistance on viral adaptation: hepatitis C virus as a case study

[91] Approaches to hepatitis C treatment and cure using NS5A inhibitors

[92] Safety and efficacy of entecavir for the treatment of chronic hepatitis B

[93] Current treatment of choice for chronic hepatitis C infection

[94] New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents

[95] New approaches in the management of chronic hepatitis B: role of tenofovir

[96] Hepatitis C virus-associated hepatocellular carcinoma as a second primary malignancy: exposing an overlooked presentation of liver cancer

[97] Decreased hepatocellular carcinoma tumor burden with the achievement of hepatitis C virus sustained virologic response: unlocking the potential of T-cell-mediated immunosurveillance

[98] Liver resection versus radiofrequency ablation for hepatitis B virus-related small hepatocellular carcinoma

[99] Clinical significance of vascular endothelial growth factor in hepatitis C related hepatocellular carcinoma in Egyptian patients

[100] Emerging role of dual antiplatelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma

[101] Telaprevir-containing regimen for treatment of hepatitis C virus infection in patients with hepatocellular carcinoma awaiting liver transplantation: a case series